ESTRO 2024 - Abstract Book

S1296

Clinical - Head & neck

ESTRO 2024

increased risk of local recurrence (95% CI: 1.0-6.4, P=0.047), and Group 3 patients had a 5.9-fold increased risk of local recurrence (95% CI: 2.6-12.9, P=0.0001).